Iron chelator in dialysis fluid for sepsis-related kidney injury
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if adding an iron chelator (MEX-CD1) to the dialysis fluid can help remove harmful iron from the blood in patients with sepsis-related acute kidney injury who need continuous dialysis. It may reduce damage to the kidneys and other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are in the intensive care unit (ICU) with sepsis and acute kidney injury needing continuous dialysis
- You meet the definition of sepsis (infection with organ problems) and stage 3 kidney injury
- You have specific reasons for dialysis, like high potassium, severe acidosis, or fluid in the lungs not helped by other treatments
- You or your legal representative can give informed consent, and you have health insurance
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of dialysis (hemodialysis and hemodiafiltration) to see which is better at removing waste from the blood in ICU patients with sudden kidney failure. It may help doctors choose the best treatment for you.
This trial tests whether a special type of dialysis filter (oXiris) helps reduce blood clotting problems in patients with septic shock and kidney failure. It may offer a better option for those needing kidney support in the ICU.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial tests if a new drug, AZD4144, can help people with sepsis-related acute kidney injury in the ICU. It aims to see if the drug can improve kidney recovery and reduce complications.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.